CD74 and acute kidney injury: Further study also shows that treatment with RPS19 is capable of attenuating cisplatin-induced AKI by inhibiting MIF/CD74/NF-κB-mediated renal inflammation, which includes suppressing TNF-α and MCP-1 expression and the infiltration of F4/80+ macrophages, neutrophils, and CD3+ T cells in the AKI kidney [47].